Vitreo-Retinal Associates, Michigan Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2011
NCT01473251
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Louis C. Glazer, MD | Vitreo Retinal Associates | Vitreo-Retinal Associates | Vitreo-Retinal Associates, Michigan | Vitreo Retinal Associates, PA | Vitreo-Retinal Associates, PC

Active Ingredients

Drugs in Phase 4 Trials (1)

ranibizumab (lucentis) (4 trials)

Drugs in Phase 3 Trials (1)

acetylcysteine (mucomyst) (1 trial)

Drugs in Phase 2 Trials (1)

ico-007 (1 trial)

Drugs in Other Trials (1)

bevacizumab (avastin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Edema (Phase 4)

Macular Edema (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 4